EA202091871A1 - Поливалентное антитело - Google Patents
Поливалентное антителоInfo
- Publication number
- EA202091871A1 EA202091871A1 EA202091871A EA202091871A EA202091871A1 EA 202091871 A1 EA202091871 A1 EA 202091871A1 EA 202091871 A EA202091871 A EA 202091871A EA 202091871 A EA202091871 A EA 202091871A EA 202091871 A1 EA202091871 A1 EA 202091871A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- region
- binding domain
- additional binding
- linker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Изобретение относится к поливалентному антителу, которое содержит основной участок антитела, который содержит два связывающих домена; и по меньшей мере один дополнительный связывающий домен, причем основной участок антитела присоединен к по меньшей мере одному дополнительному связывающему домену посредством линкера, при этом каждый связывающий домен основного участка антитела и каждый из по меньшей мере одного дополнительного связывающего домена имеет общую вариабельную область, и при этом линкер содержит шарнирную последовательность или последовательность, полученную из шарнирной последовательности. Изобретение также относится к поливалентному антителу, которое содержит основной участок антитела, который содержит два связывающих домена; и по меньшей мере один дополнительный связывающий домен, причем по меньшей мере один дополнительный связывающий домен содержит область CH1 и присоединен к основному участку антитела посредством указанного линкера, связывая вариабельную область основного участка антитела с областью CH1, и при этом поливалентное антитело связывается с по меньшей мере тремя разными эпитопами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862650467P | 2018-03-30 | 2018-03-30 | |
PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091871A1 true EA202091871A1 (ru) | 2021-06-22 |
Family
ID=66349617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091871A EA202091871A1 (ru) | 2018-03-30 | 2019-03-29 | Поливалентное антитело |
Country Status (17)
Country | Link |
---|---|
US (1) | US11952424B2 (ru) |
EP (1) | EP3774885A2 (ru) |
JP (1) | JP2021519610A (ru) |
KR (1) | KR20200139189A (ru) |
CN (1) | CN111936514A (ru) |
AR (1) | AR115320A1 (ru) |
AU (2) | AU2019243665B2 (ru) |
BR (1) | BR112020019795A2 (ru) |
CA (1) | CA3094318A1 (ru) |
EA (1) | EA202091871A1 (ru) |
IL (1) | IL277672A (ru) |
MA (1) | MA52212A (ru) |
MX (1) | MX2020010267A (ru) |
PH (1) | PH12020551504A1 (ru) |
SG (1) | SG11202009036YA (ru) |
TW (1) | TW202003569A (ru) |
WO (1) | WO2019190327A2 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111936514A (zh) | 2018-03-30 | 2020-11-13 | 美勒斯公司 | 多价抗体 |
US20220380440A1 (en) | 2018-12-31 | 2022-12-01 | Merus N.V. | Truncated multivalent multimers |
US20220073649A1 (en) | 2018-12-31 | 2022-03-10 | Merus N.V. | Mixed binding domains |
TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
MX2021013646A (es) | 2019-05-09 | 2022-01-31 | Merus Nv | Dominios variantes para las proteínas multimerizantes y su separación. |
IL294181A (en) | 2019-12-24 | 2022-08-01 | Merus Nv | tgf-beta-rii binding proteins |
CA3166407A1 (en) | 2020-01-29 | 2021-08-05 | Merus N.V. | Means and method for modulating fimmune cell engaging effects |
CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
IL298394A (en) | 2020-05-21 | 2023-01-01 | Merus Nv | Methods and means for producing ig-like molecules |
WO2023166420A1 (en) * | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2023201309A1 (en) * | 2022-04-13 | 2023-10-19 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2 and/or cd28 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
ES2528794T3 (es) * | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
CA2417185A1 (en) * | 2000-07-25 | 2002-01-31 | Shui-On Leung | Multivalent target binding protein |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2147594B1 (en) | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
CA2762837C (en) | 2009-05-20 | 2021-08-03 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
ES2542744T3 (es) | 2009-12-17 | 2015-08-11 | Novimmune Sa | Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
MX360109B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
SI2900694T1 (sl) * | 2012-09-27 | 2018-12-31 | Merus N.V. | Bispecifična IGG protitelesa kot vključitelji T-celic |
JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Bcmaに対する抗体の選択のための方法 |
EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
JP6706578B2 (ja) * | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリン及びその使用 |
NZ724013A (en) | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
IL301147A (en) | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
CN113549153A (zh) | 2014-05-29 | 2021-10-26 | 宏观基因有限公司 | 三特异性结合分子和其使用方法 |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
AU2015329966A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer |
ES2850325T3 (es) | 2014-10-09 | 2021-08-27 | Engmab Sarl | Anticuerpos biespecíficos contra CD3epsilon y ROR1 |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
CN108026174B (zh) * | 2015-07-10 | 2023-02-17 | 美勒斯公司 | 人cd3结合抗体 |
SI3331910T1 (sl) | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
AU2016340764B2 (en) * | 2015-10-23 | 2023-06-01 | Fundació lnstitut de Recerca Biomèdica (IRB Barcelona) | Binding molecules that inhibit cancer growth |
CN109476741B (zh) | 2016-03-25 | 2023-02-24 | 拜奥穆尼克斯制药 | 与cd38和pd-l1结合的分子 |
MX2018013038A (es) * | 2016-04-27 | 2019-03-28 | Pfizer | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. |
JP7258556B2 (ja) | 2016-04-28 | 2023-04-17 | ビオミューネクス・ファルマシューティカル | Egfr及びher2をターゲティングする二重特異性抗体 |
BR112019005895A2 (pt) | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
KR102617264B1 (ko) | 2016-10-19 | 2023-12-29 | 인벤라 인코포레이티드 | 항체 구조물 |
BR112019008426A2 (pt) | 2016-11-02 | 2019-09-03 | Engmab Sarl | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo |
EP3600413A1 (en) * | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
WO2018182420A1 (en) * | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
EP3649155A1 (en) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
TW201920275A (zh) * | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
EA202090003A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
MX2020001432A (es) * | 2017-08-09 | 2020-03-20 | Merus Nv | Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet). |
WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
CN111936514A (zh) | 2018-03-30 | 2020-11-13 | 美勒斯公司 | 多价抗体 |
US20220073649A1 (en) * | 2018-12-31 | 2022-03-10 | Merus N.V. | Mixed binding domains |
MX2021013646A (es) * | 2019-05-09 | 2022-01-31 | Merus Nv | Dominios variantes para las proteínas multimerizantes y su separación. |
EP4065158A2 (en) * | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
CA3166407A1 (en) * | 2020-01-29 | 2021-08-05 | Merus N.V. | Means and method for modulating fimmune cell engaging effects |
-
2019
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko active Search and Examination
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en active Application Filing
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 JP JP2021502692A patent/JP2021519610A/ja active Pending
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111936514A (zh) | 2020-11-13 |
SG11202009036YA (en) | 2020-10-29 |
WO2019190327A8 (en) | 2021-06-17 |
AU2023222983A1 (en) | 2023-09-21 |
PH12020551504A1 (en) | 2021-09-13 |
WO2019190327A2 (en) | 2019-10-03 |
MA52212A (fr) | 2021-02-17 |
AU2019243665A1 (en) | 2020-10-08 |
TW202003569A (zh) | 2020-01-16 |
CA3094318A1 (en) | 2019-10-03 |
IL277672A (en) | 2020-11-30 |
JP2021519610A (ja) | 2021-08-12 |
MX2020010267A (es) | 2020-11-06 |
WO2019190327A3 (en) | 2019-11-14 |
BR112020019795A2 (pt) | 2021-01-05 |
AU2019243665B2 (en) | 2023-06-01 |
US11952424B2 (en) | 2024-04-09 |
AR115320A1 (es) | 2020-12-23 |
EP3774885A2 (en) | 2021-02-17 |
US20190352401A1 (en) | 2019-11-21 |
KR20200139189A (ko) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091871A1 (ru) | Поливалентное антитело | |
PH12019502282A1 (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
CL2019001828A1 (es) | Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb. | |
PH12021550662A1 (en) | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously | |
WO2019086500A3 (en) | Bispecific 2+1 contorsbodies | |
MX2019012953A (es) | Anticuerpo biespecifico contra ox40 y ctla-4. | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
PH12020550825A1 (en) | Anti-c5 antibody combinations and uses thereof | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
MX2021010893A (es) | Anticuerpo biespecifico enlazado especificamente a vegf y ang2. | |
CL2020000721A1 (es) | Variantes de anticuerpo. | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
EA202191242A1 (ru) | Усеченные поливалентные мультимеры | |
ECSP21028958A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
EA202090727A1 (ru) | Варианты антител | |
EA202191941A1 (ru) | Комбинации связывающих функциональных групп, которые связываются с egfr, her2 и her3 |